Summary
AbbVie Inc.'s 2018 Form 10-K highlights a year of significant revenue growth, driven by its immunology and oncology portfolios. Total net revenues reached $32.8 billion, a 16% increase, largely propelled by strong performance from HUMIRA, IMBRUVICA, and MAVYRET, alongside continued growth from VENCLEXTA. Despite robust top-line growth, the company faced a substantial intangible asset impairment charge related to its Stemcentrx acquisition, impacting net earnings. AbbVie demonstrated a commitment to shareholder returns through increased dividends and significant share repurchases. The company is actively managing the impact of HUMIRA's biosimilar competition in Europe and anticipates continued diversification of its revenue streams through pipeline advancements in immunology, oncology, and neuroscience. Looking ahead, AbbVie is focused on driving further pipeline progression and expanding into new therapeutic areas. Management emphasized continued investment in key growth brands and the advancement of new medicines. Key risks highlighted include the ongoing expiration of patent protection, potential biosimilar competition, and the inherent uncertainties in research and development. The company's financial health remains strong, supported by substantial operating cash flows and a solid credit facility, though it continues to navigate pricing pressures and regulatory complexities in the pharmaceutical industry.
Financial Highlights
55 data points| Revenue | $32.75B |
| Cost of Revenue | $7.72B |
| Gross Profit | $25.04B |
| SG&A Expenses | $7.40B |
| Operating Expenses | $26.37B |
| Operating Income | $6.38B |
| Interest Expense | $1.35B |
| Net Income | $5.69B |
| EPS (Basic) | $3.67 |
| EPS (Diluted) | $3.66 |
| Shares Outstanding (Basic) | 1.54B |
| Shares Outstanding (Diluted) | 1.55B |
Key Highlights
- 1AbbVie reported total net revenues of $32.8 billion in 2018, a 16% increase year-over-year, driven by strong performance across its key therapeutic areas.
- 2HUMIRA remained the largest revenue contributor, accounting for approximately 61% of total net revenues, with continued growth in the US, though facing biosimilar competition internationally.
- 3Significant growth was seen in the oncology portfolio, with IMBRUVICA revenues up 39% and VENCLEXTA revenues more than doubling, indicating strong market penetration.
- 4The company incurred a substantial pre-tax intangible asset impairment charge of $5.1 billion related to the Stemcentrx acquisition, significantly impacting net earnings for the year.
- 5AbbVie returned significant value to shareholders, increasing its quarterly cash dividend by 11.5% and repurchasing approximately $10.7 billion of its common stock.
- 6The company faces ongoing patent expiration risks, particularly for HUMIRA, and notes that biosimilar competition in Europe has begun, with US biosimilar competition not expected until 2023.
- 7AbbVie is actively investing in its R&D pipeline, with over 60 compounds/indications in clinical development, focusing on immunology, oncology, and neuroscience.